Novo Nordisk Raises Full-Year Outlook Following Strong Wegovy Sales
Novo Nordisk reported quarterly earnings that exceeded market expectations, driven primarily by robust sales of its weight-loss drug, Wegovy. The strong performance has prompted the Danish pharmaceutical company to upwardly revise its full-year financial outlook. The results represent a strategic effort for Novo Nordisk to regain competitive momentum in the obesity treatment market. This follows a challenging year where the company faced increased competition from rival Eli Lilly.
Topics: earnings beat pharmaceuticals weight-loss drugs
Part of the story Cloudflare Shares Surge Following Strong Q3 Results and Raised Full-Year Guidance (85 articles)